BackgroundTo evaluate the association between tirzepatide use and 1‐year risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease, compared with GLP‐1 (glucagon‐like peptide‐1) receptor agonists.
